CSL posts FY profit above guidance

Group tips profit growth of 10% for current year despite economic headwinds.

Blood products and vaccine supplier CSL Ltd is tipping profit growth of 10% for the current year despite economic headwinds weighing on trading conditions, after posting a bumper full-year net profit. 

Investors were unimpressed by the news. At 1205 AEST shares in the company fell 2.76% to $65.93 against a benchmark index rise of 0.01%.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles